ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Flt3-Ligand Levels in Sjögrens Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01470638
Recruitment Status : Recruiting
First Posted : November 11, 2011
Last Update Posted : July 5, 2017
Sponsor:
Information provided by (Responsible Party):
Göteborg University

Brief Summary:
The study aims to correlate levels of Flt3-ligand in Cerebrospinal Fluid (CSF) and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome.

Condition or disease
Sjogrens Syndrome

Detailed Description:
The study aims to correlate levels of Flt3-ligand in CSF and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome.

Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Analyzes of Cerebrospinal Fluid in Autoimmune Systemic Diseases
Study Start Date : June 2009
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

U.S. FDA Resources




Primary Outcome Measures :
  1. Correlate levels of Flt3-ligand in Cerebrospinal Fluid (CSF) and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome [ Time Frame: June 2009 - June 2015 ]

Biospecimen Retention:   Samples Without DNA
Serum, cerebrospinal fluid


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The rheumatology clinic at Sahlgrenska University hospital, Gothenburg, Sweden
Criteria

Inclusion Criteria:

  • fulfill the ACR-criteria for primary Sjogrens syndrome,
  • age above 18 years old

Exclusion Criteria:

  • other CNS-disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01470638


Contacts
Contact: Mats Dehlin, PhD-student +46-31-3424173 mats.dehlin@vgregion.se

Locations
Sweden
Dept of Rheumatology, Sahlgrenska University Hospital Recruiting
Gothenburg, Sweden, 413 46
Contact: Mats Dehlin, PhD student    +46-31-3424173    mats.dehlin@vgregion.se   
Principal Investigator: Mats Dehlin, MD         
Sponsors and Collaborators
Göteborg University

Responsible Party: Göteborg University
ClinicalTrials.gov Identifier: NCT01470638     History of Changes
Other Study ID Numbers: Flt3-L SS
First Posted: November 11, 2011    Key Record Dates
Last Update Posted: July 5, 2017
Last Verified: July 2017

Keywords provided by Göteborg University:
Flt3-L
CSF

Additional relevant MeSH terms:
Sjogren's Syndrome
Syndrome
Disease
Pathologic Processes
Arthritis, Rheumatoid
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Xerostomia
Salivary Gland Diseases
Mouth Diseases
Stomatognathic Diseases
Dry Eye Syndromes
Lacrimal Apparatus Diseases
Eye Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases